Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

AstraZeneca Halts NXY-059 Development Following SAINT II Stroke Results

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm returns the neuroprotectant to partner Renovis after pivotal trial in acute ischemic stroke fails to show statistical significance.

You may also be interested in...



Outlook For AstraZeneca/AtheroGenics’ Candidate May Sink On ARISE Trial Results

A Phase III clinical study evaluating the atherosclerosis candidate failed to meet its primary endpoint.

Outlook For AstraZeneca/AtheroGenics’ Candidate May Sink On ARISE Trial Results

A Phase III clinical study evaluating the atherosclerosis candidate failed to meet its primary endpoint.

AstraZeneca Hits Anti-Infective Target With Arrow Acquisition

Acquisition of U.K. biotech reflects AstraZeneca's core therapeutic focus in infection, the company says.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Rare Disease Body Wants EU Legislative Overhaul To Address Orphan Definitions & Incentives

‘Gene Silencing’ Drug Oxlumo Wins English Funding After Alnylam Improves Discount

Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation

Medicare Seeks Input On Dispute Resolution, Civil Penalties For Rx Pricing Program

See All
UsernamePublicRestriction

Register

PS063269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By